In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor

The PI3K/AKT pathway plays an important role in the initiation and progression of cancer, and the drug development efforts targeting this pathway with therapeutic interventions have been advanced by academic and industrial groups. However, the clinical outcome is moderate. Combination of inhibition...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yi, Hall, Terence, Eathiraj, Sudharshan, Wick, Michael J., Schwartz, Brian, Abbadessa, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Preclinical Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404396/
https://www.ncbi.nlm.nih.gov/pubmed/28240679
http://dx.doi.org/10.1097/CAD.0000000000000486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404396/
https://www.ncbi.nlm.nih.gov/pubmed/28240679
http://dx.doi.org/10.1097/CAD.0000000000000486

Ejemplares similares